Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients
- 1 May 1989
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 29 (1) , 57-62
- https://doi.org/10.1007/bf00199917
Abstract
Both phytohemagglutinin-induced cytotoxicity and recombinant-interleukin-2 (rIL-2)-induced lymphokine-activated killer (LAK) activity against noncultured melanoma cells were significantly reduced when peripheral blood mononuclear cells (PBMC) from patients with metastatic melanoma were incubated in RPMI medium 1640 and 10% autologous human serum instead of 10% fetal calf serum, while serum from either healthy donors or patients with primary melanoma did not affect the level of cytotoxicity. The serum-mediated suppression was not restricted by major histocompatibility complex and was time-dependent. Addition of 10% human serum from the patients with metastatic melanoma [HS-Pt(m)] to the culture of PBMC with rIL-2 at the same time or 1 day after incubation significantly inhibited LAK activity. However, addition of 10% HS-Pt(m) 2 or 3 days after incubation did not inhibit LAK activity. Incubation of PBMC for 2 h with a high dose (104 U/ml) of rIL-2 in the presence of 10% HS-Pt(m), followed by incubation in the absence of either rIL-2 or HS-Pt(m), did not affect LAK cell activity. These results suggest that HS-Pt(m) inhibits the early stage of LAK cell differentiation, rather than the binding of rIL-2 to PBMC or a later stage in the differentiation. In contrast to PBMC, monocyte-depleted peripheral blood lymphocytes exhibited comparable levels of LAK activity when cultured with rIL-2 either in 10% fetal calf serum, 10% human serum from healthy donors or 10% HS-Pt(m). Addition of purified autologous monocytes to the culture of monocyte-depleted peripheral blood lymphocytes with rIL-2 suppressed LAK cell induction when 10% HS-Pt(m) was present. Thus serum-mediated suppression of LAK cell induction is largely dependent on the presence of monocytes, which may produce a secondary inhibitor that acts on lymphocytes. Addition of indomethacin to the culture did not reverse this monocyte-dependent serum-mediated suppression in a majority of cases, suggesting that prostaglandin E2 does not have a major role in the suppression.Keywords
This publication has 17 references indexed in Scilit:
- RECOMBINANT INTERLEUKIN-4 (RIL4) INHIBITS INTERLEUKIN-2-INDUCED ACTIVATION OF PERIPHERAL-BLOOD LYMPHOCYTES1988
- Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cellsCellular Immunology, 1987
- Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.The Journal of Immunology, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.The Journal of Immunology, 1987
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- CHARACTERIZATION AND MODULATION OF HUMAN LYMPHOKINE (INTERLEUKIN-2) ACTIVATED KILLER-CELL INDUCTION1986
- Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor.1985
- Lymphokine-induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic response.The Journal of Immunology, 1985
- Sequential studies on cell‐mediated tumor immunity and blocking serum activity in ten patients with malignant melanomaInternational Journal of Cancer, 1973